Srivastava Amitabh, Hornick Jason L, Li Xiaohong, Blount Patricia L, Sanchez Carissa A, Cowan David S, Ayub Kamran, Maley Carlo C, Reid Brian J, Odze Robert D
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
Am J Gastroenterol. 2007 Mar;102(3):483-93; quiz 694. doi: 10.1111/j.1572-0241.2007.01073.x.
Previous studies that evaluated extent of high-grade dysplasia (HGD) as a risk factor for esophageal adenocarcinoma (EA) in Barrett's esophagus (BE) were conflicting, and no prior study has evaluated extent of low-grade dysplasia (LGD) as a risk factor. The aim of this discovery study was to evaluate the hypothesis that extent of LGD and HGD are risk factors for progression to EA.
We evaluated baseline biopsies from 77 BE patients with dysplasia including 44 who progressed to EA and 33 who did not progress during follow-up. The total numbers of LGD and HGD crypts were determined separately by counting all crypts and the extent of LGD, HGD, and total dysplasia were correlated with EA outcome.
Thirty-one and 46 patients had a maximum diagnosis of LGD and HGD, respectively. When the crypts were stratified by dysplasia grade, the mean number of LGD crypts per patient was borderline higher in progressors (93.9) compared with nonprogressors (41.2, P= 0.07), and the mean proportion of LGD crypts per patient was significantly higher in progressors (46.4%vs 26.0%, P= 0.037). Neither the mean number of HGD crypts per patient (P= 0.14) nor the mean proportion of HGD crypts per patient (P= 0.20) was significantly associated with EA outcome.
The extent of LGD is a significant risk factor for the development of EA in BE in this study. Although the presence of HGD is significantly associated with a greater relative risk for development of EA, the extent of HGD was not an independent risk factor for progression.
既往评估高级别异型增生(HGD)范围作为巴雷特食管(BE)中食管腺癌(EA)危险因素的研究结果相互矛盾,且此前尚无研究评估低级别异型增生(LGD)范围作为危险因素。本探索性研究的目的是评估LGD和HGD范围是进展为EA的危险因素这一假设。
我们评估了77例有异型增生的BE患者的基线活检样本,其中44例在随访期间进展为EA,33例未进展。通过计数所有隐窝分别确定LGD和HGD隐窝的总数,并将LGD、HGD和总异型增生的范围与EA结局相关联。
分别有31例和46例患者的最高诊断为LGD和HGD。当按异型增生级别对隐窝进行分层时,进展组患者的平均LGD隐窝数(93.9)略高于未进展组(41.2,P = 0.07),且进展组患者的平均LGD隐窝比例显著高于未进展组(46.4%对26.0%,P = 0.037)。患者的平均HGD隐窝数(P = 0.14)和平均HGD隐窝比例(P = 0.20)均与EA结局无显著关联。
在本研究中,LGD范围是BE中EA发生的重要危险因素。虽然HGD的存在与EA发生的相对风险显著相关,但HGD范围不是进展的独立危险因素。